The Life Sciences team advised bit.bio on its collaboration and option agreement with BlueRock Therapeutics for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics.
Under the terms of the agreement, bit.bio will use its machine learning powered discovery platform to identify transcription factor (TF) combinations for reprogramming iPSCs into Tregs. The agreement also includes options for BlueRock to license bit.bio’s opti-ox precision cell programming technology to control the expression of TF combinations within Treg cell therapies. opti-ox uses a dual genomic safe harbour approach to cell programming, and bit.bio uses opti-ox to drive the rapid TF-mediated conversion of iPSCs into highly defined cell types in a single step.
bit.bio is a synthetic biology company focused on human cells that is advancing medicine and enabling curative treatments.
BlueRock Therapeutics is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases.
The Goodwin team was led by Kathleen Kean, Paresh Kumar, and Alexandra Haas, with invaluable support from Kevin Kabler, Julie Tibbets, Elizabeth Mulkey and Paul Jin.
For more details, read the press release.